SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is trending due to a strategic partnership with Crypto.com to launch an exclusive U.S. prediction markets platform, coupled with plans for sports betting expansion. The community is actively discussing the stock's significant surge, high volume, and potential for a short squeeze given its low float. However, some are also debating the possibility of future share offerings amidst the intense market activity.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending sharply following a stellar earnings report that surpassed expectations with strong margins and aggressive capital expenditure plans, driven by persistent AI chip demand. The community is actively discussing the CEO's "AI megatrend" outlook, interpreting the results as a significant bullish indicator for the entire semiconductor sector. This strong performance is expected to generate positive momentum for related companies in the AI supply chain.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial (RILY) is experiencing an intense surge of conversation following its Q3 financial report release, which arrived significantly ahead of its NASDAQ compliance deadline and indicated a strong return to profitability. The news has ignited fervent discussions among traders, who are anticipating a major short and gamma squeeze due to high short interest and renewed confidence as delisting fears subside. The community is actively debating the potential for a substantial upward movement, with many drawing parallels to historical market squeezes like CVNA or GME.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently a focal point for investors, navigating ongoing Wall Street downgrades alongside intense discussion around a potential credit card interest rate cap and its implications for the company's Buy Now Pay Later services. Despite significant community frustration regarding recent stock performance and calls for leadership changes, many perceive PYPL as fundamentally undervalued, citing robust financials and strategic AI partnerships. This creates a deeply divided sentiment, with some confidently calling a bottom while others anticipate further price erosion amid concerns of market manipulation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is experiencing a surge due to intensified geopolitical focus on Greenland's vast critical mineral resources, highlighted by the formation of a U.S., Denmark, and Greenland working group on security and resource development. Community discussion is buzzing with expectations of significant U.S. investment and supply chain security, fueling heavy trading volume and speculation about a potential short squeeze for the company. This dynamic positions CRML as a central player in the global race for essential rare earth elements.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending with renewed investor interest, fueled by Cantor Fitzgerald's reiterated "Overweight" rating and $18 price target, ahead of its J.P. Morgan Healthcare Conference presentation. The community is buzzing with speculation about new Matrix-M platform partnerships, particularly in the oncology sector, and the potential for a significant short squeeze given the high short interest. This optimism is tempered by ongoing shareholder frustration regarding management's execution and hopes for strategic changes, including a potential proxy fight.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending sharply higher, propelled by robust sentiment across the semiconductor industry amid encouraging economic data and positive earnings reports from key players like TSMC. The community is actively debating its substantial rally, with many anticipating continued upside driven by insatiable AI demand, while others signal caution about an "AI bubble" and potential for profit-taking given its leveraged nature. Upcoming tech conferences, such as CES, further highlight the sector's pivotal role in technological advancements.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy (DVN) is seeing increased discussion driven by significant bullish options activity and multiple analyst upgrades, as the community actively speculates on a potential dividend hike and the stock's compelling valuation. Investors are highlighting DVN's strong free cash flow and domestic assets, framing it as an undervalued "cash machine" within the energy sector, while anticipating a potential re-rating and a return to the $40 threshold.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending amidst reports that Sanofi is preparing an improved takeover bid after its initial offer was rejected, sparking community discussions about a potential bidding war. This acquisition interest coincides with high anticipation for the upcoming SOL-1 Phase 3 trial data for AXPAXLI, expected in Q1 2026, which many believe could significantly re-rate the company. Investors are closely watching, noting institutional accumulation and the potential for the long-acting wet AMD therapy to reshape the market.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is experiencing heightened investor interest and significant trading volume, fueled by speculation of a gamma squeeze driven by expiring call options and community enthusiasm for its Optical Interposer technology. This core innovation for high-speed, energy-efficient AI data center interconnects is generating strong anticipation for upcoming news on strategic partnerships and product developments, despite reports of some online brokers restricting buy orders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve

enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.

Medical device company enVVeno Medical Corporation (NVNO) on Wednesday announced that the U.S. Food &amp; Drug Administration (FDA) has refused to approve its application for its lead product, VenoValve, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).Following the announcement, NVNO shares plunged 71% by Wednesday afternoon, at the time of writing.Severe deep chronic venous insufficiency (CVI) is a long-term condition where the veins in the legs have difficulty returning blood to the heart, leading to blood pooling and various symptoms like swelling, aching, and skin changes. This occurs primarily due to damaged or weakened valves within the deep leg veins.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVNO">NVNO</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while retail chatter rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:563/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_12_41_02_PM_png_bca2208bb7.webp" alt="NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="61"><figcaption>NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the company renegotiating with the FDA.<stembedurl>https://stocktwits.com/Flying_Trader2/message/625960642</stembedurl>Another user said that they see no value in the company with the VenoValve rejection.<stembedurl>https://stocktwits.com/kmx_swing/message/625941525</stembedurl>The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://envveno.com/envveno-receives-not-approvable-letter-from-the-fda-for-the-venovalve/">said</a> in a letter that it completed its review of the company’s application for VenoValve but has decided that it is unable to approve it in its current form. The agency said that data generated by the company for the application was not sufficient on its own to determine the favorability of the benefit-risk profile for VenoValve.The FDA also raised concerns about bias and the possibility that clinical improvement occurred as a result of the patients being enrolled in a study. The agency further raised safety concerns, which were attributed to the VenoValve open surgical procedure, and which required re-hospitalizations.CEO Robert Berman said that the company is disappointed by the FDA’s decision and highlighted that a high percentage of patients in a study showed significant clinical improvement after receiving VenoValve. Berman added that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of the device.The firm’s next steps may include a meeting with the FDA to discuss requirements for a potential resubmission of the VenoValve or appeal of the decision, along with appropriate next steps.NVNO stock is down by 59% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-says-tesla-model-yl-might-not-ever-come-to-us-markets/chsitLlRdhq">Elon Musk Said Tesla’s Model Y L Might Not Ever Come To US Markets – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?

enVVeno Medical Corporation CEO Robert Berman said that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of its VenoValve device. 

Equity

This account has been verified as an official NVNO representative.

Verified Account

enVVeno Medical

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include VenoValve and enVVe. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

enVVeno Medical Corporation

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

NVNO
enVVeno Medical Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVNO News

NVNOenVVeno Medical Corporation